Eculizumab in atypical hemolytic-uremic syndrome.

Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature

Atypical hemolytic uremic syndrome (aHUS) patients treated with eculizumab may require higher doses to achieve and maintain optimal clinical response. Further studies are warranted to elucidate optimal dosing regimens of eculizumab in aHUS patients, and whether dosing regimens can be predicted based on mutational status, eculizumab levels, or other testing.

Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3 Eculizumab para el tratamiento de un síndrome urémico hemolítico

Recurrent Atypical Hemolytic Uremic Syndrome Post-Renal Transplantation: Case Report Treated with Eculizumab

Atypical Hemolytic Uremic syndrome is disease that could results in end stage renal disease and subsequently requiring hemodialysis or renal transplant. It also could recur after renal transplant, which poses a challenge to diagnose and treat given the complexity of immunosuppressive medications. Proper preparation before the transplant and vigilant post transplant monitoring is crucial to pres...

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

This case report describes how eculizumab reversed neurologic impairment and improved renal damage in severe atypical hemolytic uremic syndrome. A 50-year-old female, after presenting with diarrhea and abdominal pain, developed pancolitis, acute renal failure, and thrombocytopenia. The patient underwent total abdominal colectomy. Pathology confirmed ischemic colitis with scattered mesenteric mi...

Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab

BACKGROUND Atypical hemolytic uremic syndrome is a rare disorder which is known to cause acute thrombotic microangiopathy during pregnancy with poor maternal and fetal outcomes. Atypical hemolytic uremic syndrome is caused mostly by dysregulation of alternative complement pathway secondary to genetic mutations. Most of the cases reported have been in the post-partum period. We report a rare cas...

Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supporting eculizumab discontinuation, which may be associated with high collateral risks such as los...